



Phil Mullin

## *Bill Analysis*

*Legislative Service Commission*

### **H.B. 325**

126th General Assembly  
(As Introduced)

**Reps. Carmichael, Perry, C. Evans, Seitz, Carano, Kearns, Raga, Combs, Schaffer, Webster, Reinhard, Harwood, Setzer, Gibbs, Blasdel, Hartnett**

---

### **BILL SUMMARY**

- Creates the Commission on the Future of Cancer Care in Ohio and requires it to conduct an updated analysis of Ohio's clinical cancer assets and develop recommendations for accelerating Ohio's cancer care.

---

### **CONTENT AND OPERATION**

#### **Membership**

The bill creates the Commission on the Future of Cancer Care in Ohio, consisting of 29 members. The House Speaker must appoint to the Commission two House members of the same political party as the Speaker, the House Minority Leader must appoint one House member of the same political party as the Minority Leader, the Senate President must appoint two Senate members of the same political party as the President, and the Senate Minority Leader must appoint one Senate member of the same party as the Minority Leader. The House Speaker and Senate President also must each appoint one member of the general public who has suffered from cancer and jointly appoint one member of the general public who is the parent of a child who suffers from pediatric cancer. (Section 1(A).)

In addition, each of the following must designate one person to serve on the Commission:

- Department of Health.
- Department of Development.
- Case Western Reserve University.
- University of Cincinnati Medical Center.

- The Ohio State University Medical Center.
- Cleveland Clinic.
- American Cancer Society, Ohio Chapter.
- Ohio Hospital Association.
- Ohio State Medical Association.
- Ohio Chapter of the American Academy of Pediatrics.
- Ohio Association of Children's Hospitals.
- Ohio Cancer Research Associates.
- Ohio Chamber of Commerce.
- Ohio Association of Health Plans.
- West Virginia/Ohio Hematology and Oncology Associates.
- A rural hospital, as determined by the Ohio Hospital Association.

Omeris (see **COMMENT**) must designate as Commission members two persons who represent pharmaceutical or biotechnology companies engaged in cancer research and one person who represents a pharmaceutical contract research organization based in Ohio. Under the bill, the president of Omeris also is a Commission member and must serve as its chairperson. (Section 1(A).)

**Sources of funding**

The bill authorizes the Commission to solicit public and private grants and contract with consultants as necessary to complete its work (see below). The members of the Commission may be reimbursed for their reasonable and necessary expenses to the extent funds are available. (Section 1(B).)

**Topics of the analysis and recommendations**

The bill requires the Commission to conduct an updated analysis of Ohio's clinical cancer assets and develop recommendations for accelerating Ohio's cancer care by doing all of the following (Section 1(C)):

- Studying the feasibility of a statewide adult and pediatric clinical trials network.

- Studying state and private incentives to encourage pharmaceutical and biotechnology companies to conduct research and clinical trials in Ohio.
- Updating Ohio's clinical trials and medical privacy laws.
- Developing a statewide bio-repository and encouraging clinicians, hospitals, and patients to participate by providing federal, state, and private sector reimbursement.
- Examining the use of the Third Frontier Network.
- Examining the use of federal and state funds from the National Institutions of Health and the Third Frontier and Biomedical and Tech Transfer funds.

**Report**

Not later than one year after the bill's effective date, the Commission must submit a report to the Governor, House Speaker, Senate President, House Minority Leader, and Senate Minority Leader. It must include recommendations on the issues the bill requires the Commission to study. On submission of the report, the Commission will cease to exist. (Section 1(D).)

**COMMENT**

According to its Internet web site, Omeris, founded in 1986 as Edison BioTechnology Center, is a nonprofit organization designed to build and accelerate bioscience industry, research, and education in Ohio. The founding members of Omeris were Battelle, Proctor and Gamble Pharmaceuticals, The Cleveland Clinic Foundation, University Hospitals Health Systems, Case Western Reserve University, Ohio University, The Ohio State University, and the University of Cincinnati.

**HISTORY**

ACTION	DATE	JOURNAL ENTRY
Introduced	08-11-05	p. 1601

H0325-I-126.doc/jc

